0.4985
price down icon2.27%   -0.0116
pre-market  Pre-market:  .50   0.0015   +0.30%
loading
Elevation Oncology Inc stock is traded at $0.4985, with a volume of 398.52K. It is down -2.27% in the last 24 hours and down -24.36% over the past month. Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
See More
Previous Close:
$0.5101
Open:
$0.5041
24h Volume:
398.52K
Relative Volume:
0.19
Market Cap:
$29.52M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
-0.6006
EPS:
-0.83
Net Cash Flow:
$-38.34M
1W Performance:
-2.43%
1M Performance:
-24.36%
6M Performance:
-18.12%
1Y Performance:
-88.05%
1-Day Range:
Value
$0.4914
$0.53
1-Week Range:
Value
$0.4613
$0.53
52-Week Range:
Value
$0.4613
$5.8299

Elevation Oncology Inc Stock (ELEV) Company Profile

Name
Name
Elevation Oncology Inc
Name
Phone
(716) 371-1125
Name
Address
101 FEDERAL STREET, BOSTON
Name
Employee
34
Name
Twitter
Name
Next Earnings Date
2025-03-05
Name
Latest SEC Filings
Name
ELEV's Discussions on Twitter

Compare ELEV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ELEV
Elevation Oncology Inc
0.4985 29.52M 0 -41.95M -38.34M -0.83
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-03-25 Initiated William Blair Outperform
May-31-24 Initiated Piper Sandler Overweight
May-14-24 Initiated Stephens Overweight
Mar-01-24 Initiated JMP Securities Mkt Outperform
May-30-23 Upgrade SVB Securities Market Perform → Outperform
Dec-23-21 Initiated H.C. Wainwright Buy
View All

Elevation Oncology Inc Stock (ELEV) Latest News

pulisher
Mar 13, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

HC Wainwright Has Optimistic Outlook of ELEV Q1 Earnings - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Elevation Oncology’s (ELEV) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains Buy on Elevation Oncology stock By Investing.com - Investing.com UK

Mar 10, 2025
pulisher
Mar 10, 2025

Elevation Oncology stock holds $7 target at JMP Securities By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Elevation Oncology’s (ELEV) “Overweight” Rating Reiterated at Stephens - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Buy Recommendation for Elevation Oncology: Promising Pipeline and Strong Financial Management - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Elevation Oncology stock holds $7 target at JMP Securities - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Elevation Oncology’s (ELEV) Outperform Rating Reiterated at William Blair - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Analysts Issue Forecasts for ELEV FY2029 Earnings - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Research Analysts Offer Predictions for ELEV Q2 Earnings - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Elevation Oncology’s Future in Jeopardy: Financing Challenges Threaten Product Development - TipRanks

Mar 08, 2025
pulisher
Mar 07, 2025

Elevation Oncology Reports 2024 Financial Results and Progress - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Strategic Advancements and Financial Stability Drive Buy Rating for Elevation Oncology - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Elevation Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Elevation Oncology reports Q4 EPS (18c), consensus (22c) - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Elevation Oncology, Inc. SEC 10-K Report - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Elevation Oncology : Corporate OverviewMarch 2025 -March 06, 2025 at 04:34 pm EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Can Elevation Oncology's $93M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

Elevation Oncology Inc. (ELEV) reports earnings - Quartz

Mar 06, 2025
pulisher
Mar 04, 2025

Elevation Oncology Inc (NASDAQ: ELEV) Declines -8.57%: This $28.32 million Stock Could Go Down -1983.33% - Stocks Register

Mar 04, 2025
pulisher
Mar 03, 2025

Elevation Oncology Stock Hits 52-Week Low at $0.5 Amid Challenges - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Elevation Oncology Stock Hits 52-Week Low at $0.5 Amid Challenges By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Elevation Oncology (ELEV) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 03, 2025
pulisher
Feb 28, 2025

Elevation Oncology Inc’s (ELEV) Stock Is Harder To Predict Than You Think - Stocks Register

Feb 28, 2025
pulisher
Feb 25, 2025

Elevation Oncology to Participate in Upcoming Investor Conferences - Citizentribune

Feb 25, 2025
pulisher
Feb 25, 2025

Can Elevation Oncology's March Conference Appearances Reveal New Cancer Treatment Progress? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Brokerages Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $7.20 - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Feb 24, 2025
pulisher
Feb 18, 2025

Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - Finansavisen

Feb 18, 2025
pulisher
Feb 18, 2025

Former Elevation Oncology CSO Joins Aadi to Lead $100M ADC Portfolio Expansion - StockTitan

Feb 18, 2025
pulisher
Feb 15, 2025

Elevation Oncology, Inc. (NASDAQ:ELEV) Shares Bought by SG Americas Securities LLC - Defense World

Feb 15, 2025
pulisher
Feb 11, 2025

Are Elevation Oncology Inc (ELEV) shares a good deal now? - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

Analysts Offer Predictions for ELEV Q2 Earnings - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Keeping an Eye on Elevation Oncology Inc (ELEV) After Insider Trading Activity - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Market Recap Check: Elevation Oncology Inc (ELEV)’s Negative Finish at 0.63, Up/Down -5.85 - The Dwinnex

Feb 10, 2025
pulisher
Feb 08, 2025

Brokers Offer Predictions for ELEV Q1 Earnings - Defense World

Feb 08, 2025
pulisher
Feb 06, 2025

Goldman Sachs Group Inc. Reduces Stake in Elevation Oncology Inc. - GuruFocus.com

Feb 06, 2025
pulisher
Feb 05, 2025

JPMorgan Chase & Co. Raises Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

Feb 05, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Increases Stake in Elevation Oncology Inc - GuruFocus.com

Feb 05, 2025
pulisher
Feb 04, 2025

Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle

Feb 04, 2025
pulisher
Feb 03, 2025

Understanding ELEV stock ratios for better investment decisions - US Post News

Feb 03, 2025
pulisher
Feb 02, 2025

Elevation Oncology announces CSO departure By Investing.com - Investing.com South Africa

Feb 02, 2025
pulisher
Feb 02, 2025

Elevation Oncology announces CSO departure - MSN

Feb 02, 2025
pulisher
Feb 01, 2025

Daiichi Sankyo to promote Okuzawa to CEO - BioCentury

Feb 01, 2025
pulisher
Feb 01, 2025

Elevation Oncology Chief Scientific Officer Announces ResignationOn January 29, 2025, Elevation Oncology, Inc. (NASDAQ: ELEV) received a communication from David Dornan, Ph.D., the company’s Chief Scientific Officer, regarding his decision to resign - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

Elevation Oncology Announces CSO Resignation - TipRanks

Jan 31, 2025
pulisher
Jan 31, 2025

Vanguard Group Inc. Reduces Stake in Elevation Oncology Inc. - GuruFocus.com

Jan 31, 2025
pulisher
Jan 31, 2025

Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $7.20 Consensus PT from Analysts - Defense World

Jan 31, 2025
pulisher
Jan 26, 2025

Barclays PLC Has $43,000 Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

Jan 26, 2025

Elevation Oncology Inc Stock (ELEV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):